When I wrote about "Magic Aleve" -- a derivative of Aleve/naproxen that appears to be both G.I.-friendly and a more potent analgesic/antiinflammatory than Aleve itself -- a number of questions arose. Dr. John Wallace, CSO of Antibe, which is developing the drug called ATB-346, kindly agreed to answer them.
There hasn't been a material advance in the pharmacological treatment of pain since the 1890s, when heroin and aspirin were invented. That may change if an experimental drug being developed by a Toronto-based drug company keeps performing in advanced clinical trials. This could be huge.
Drug discovery is a long, arduous process. Chemists and biologists have been eternally looking for methods to shorten it by trying to differentiate between chemical compounds that simply pop up in a test and those that have promise as drugs. Chris Gerry, a Harvard graduate student in Prof. Stuart's Chemistry & Chemical Biology group, describes a new, elegant where DNA is used to test "good" molecules, trillions at a time.
Given therapeutics in the cancer category dominate the list is not so surprising, given the hefty price tag they yield. Where there is a great return there tends to be a great investment.
Drug discovery is a long, tortuous and impossibly difficult job. A group at the University of Warwick has come up with a mathematical model that seems to be a very big step in streamlining the process. But is it really? To answer this we need to take a look at how drugs are discovered.
Due to the opaque nature of the pharmaceutical industry’s disclosures, a study published in JAMA Internal Medicine sought to quantify a standard amount companies spent on the research and development of cancer drugs. Do these R&D costs justify such high prices and revenues?
With the recent discovery of polymyxin-resistant infection here in the U.S., there's a renewed pledge among drug developers and the government to incentivize research for developing new antibiotics, previously a seemingly abandoned effort.
A protein involved in pathological angiogenesis can serve as a new therapeutic target in the treatment of chronic liver disease, which claims nearly 50,000 lives annually. In vivo tests involving knock-out mice has shown promising results.
Researchers at the University of California have been able to successfully create a liquid blood pressure medication that can be absorbed through the skin, without the requisite skin toxicity. The implications for transdermal drug delivery are multiple and profound.
There is an op-ed in today s New York Times written by former Obama administration health guru Dr. Ezekiel Emanuel, which supposedly addresses the dire need for new antibiotics which is both wrong and misleading.
Screen Shot 2014-12-23 at 1.46.58 PMNormally, this wouldn t even make the news. A new antibiotic approved. Not only that, but it belongs to a class of antibiotics (called cephalosporins) from the class of 1960s, which is hardly novel. There are about 60 cephalosporins that have been approved since 1964, when cephalothin was launched by Lilly.
By any measure, malaria is one of the most ruthless threats to global human health. It has been estimated that the parasite a protozoan called Plasmodium kills one child per minute in Africa alone. While it used to take the lives of over one-million people each year, mostly sub-Saharan African infants and children, the number has been reduced substantially thanks to modern public-health efforts, to approximately 650,000. But this number is still unacceptable, and twenty-times that number are chronically ill from malaria.